



2025 ANNUAL REPORT

ADVANCING PATIENT VOICES INTO ACTION



LYMPHOMA
CANADA

| Education | Support | Advocacy | Research |



Table of Contents

A LETTER FROM THE CEO AND BOARD CHAIR 1

WHO WE ARE 2

OUR IMPACT 7

THANK YOU! 12

PATIENT AND CAREGIVER EDUCATION 14

SUPPORT FOR PATIENTS & FAMILIES 19

**ADVOCATING FOR EQUITABLE ACCESS
TO INNOVATIVE THERAPIES 22**

LYMPHOMA RESEARCH & DISEASE AWARENESS 25

RAISING AWARENESS 28

IN THE SPOTLIGHT 29

LOOKING AHEAD 37



A LETTER FROM THE CEO AND BOARD CHAIR

Dear Friends, Supporters, and Partners,

On behalf of the Board of Directors and team, we are pleased to share Lymphoma Canada's 2025 Annual Report.

This year has been defined by progress, purpose, and the power of patient voices. Across the country, individuals and families affected by lymphoma continue to face uncertainty, complexity, and, too often, barriers to timely diagnosis and access to treatment. In response, Lymphoma Canada has remained steadfast in its commitment to ensure that no one faces lymphoma alone—and that the lived experiences of patients meaningfully shape the systems intended to serve them.

In 2025, we strengthened our role as a national leader in patient engagement, advancing the voices of Canadians affected by lymphoma into tangible action. Through our participation in health technology assessments, collaboration with other patient organizations and industry, we worked to ensure that patient perspectives were not only heard, but reflected in critical decisions impacting access to therapies and care.

At the same time, we continued to expand and evolve our support programs to meet the diverse and changing needs of our community. From education and awareness initiatives to personalized support and mentorship services, our focus remains on delivering trusted, relevant, and compassionate resources to those navigating a lymphoma diagnosis.

None of this work would be possible without the unwavering support of our donors, volunteers, partners, and advocates. Your commitment fuels our mission and enables us to operate with integrity, accountability, and impact. We remain deeply committed to transparency, strong governance, and the responsible stewardship of the resources entrusted to us.

As we look ahead, we recognize that there is still much work to be done. However, we are confident that through continued collaboration and a shared dedication to improving outcomes, we can drive meaningful change for the lymphoma community across Canada.

Thank you for standing with us.



Antonella Rizza, CPA, CA
CEO



Angela Nikolakakos, LLM
Board Chair

WHO WE ARE



LYMPHOMA
CANADA

ORGANIZATION PRESENTATION

For more than 27 years, Lymphoma Canada has been advancing meaningful change for Canadians affected by lymphoma—ensuring that no patient or family faces this disease without trusted information, compassionate support, and a strong national voice advocating on their behalf.

Our mission is to empower patients and the lymphoma community through education, support, advocacy, and research. This mission is brought to life not by programs alone, but by the strength of a nationwide community—patients, caregivers, peer mentors, healthcare professionals, researchers, volunteers, donors, partners, and staff—working together toward better outcomes.

As the only national organization in Canada dedicated exclusively to lymphoma, Lymphoma Canada continues to serve as a trusted source of disease-specific education, a connector to support at critical moments, and a leading advocate for equitable access to care. In a healthcare landscape that is increasingly complex, personalized, and evolving, our role has never been more essential.



OUR VISION

Life unlimited
by lymphoma.

OUR MISSION

Empower patients and the lymphoma community
through education, support, advocacy and research.



Collaboration

We deliver results through teamwork both internally and externally.




Compassion

Our work is rooted in empathy, respect and kindness.



Excellence

We are passionate, determined and committed to being highly efficient and effective.



Inclusivity

We respect equity, diversity and accessibility in our programming and operations.



Influence

We are professional and dedicated to making an impactful difference that is evidence-based and legacy-worthy.



Integrity

We are honest, transparent and adhere to high ethical standards, equality and fairness.



Innovation

We are resourceful, empowered and progressive.



2025 Board of Directors

Angela Nikolakakos | *Chair* | Toronto, ON
Claudio Grossi | *Vice Chair* | Woodbridge, ON
Pranav Bhardwaj | *Treasurer* | Toronto, ON
Tom Gee | *Director* | Edmonton, AB
David Kerr | *Director* | Toronto, ON
Robert Michon | *Director* | Gatineau, QC
Eddy Nason | *Director* | Ottawa, ON
Lawrence Reiter | *Director* | Toronto, ON
Matthew Roebuck | *Director* | Toronto, ON
Dr. Pamela Skrabek | *Director* | Winnipeg, MB
Blair White | *Director* | St. John's, NL

Honorary Governors

Alyssa Burkus | Oakville, ON
Joseph Connors | Victoria, BC
Terry Creighton | Toronto, ON
Paul Henderson | Mississauga, ON
Nick Iozzo | Vaughan, ON
Anwar Knight | Toronto, ON
Dr. John Kuruvilla | Toronto, ON
Mika Midolo | Toronto, ON
Harold Olney | Montreal, QC
Laurie Sehn | Vancouver, BC
Sharlene Smith | Victoria, BC
Deb Sterritt | Salmon Arm, BC
John Sutherland | Hamilton, ON
Sabina Vohra-Miller | Toronto, ON
Paul Weingarten | Toronto, ON

Scientific Advisory Committee

Dr. John Kuruvilla | *Chair*; MD, FRCPC
Princess Margaret Cancer Centre
Toronto, ON

Dr. Mark Bosch, MD, FRCPC
Saskatchewan Cancer Agency
Regina, SK

Dr. Graeme Fraser, MD, FRCPC
Juravinski Cancer Centre
Hamilton, ON

Dr. David Hodgson, MD, MPH, FRCPC
Princess Margaret Cancer Centre
Toronto, ON

Dr. David MacDonald, MD, FRCPC
The Ottawa Hospital
Ottawa, ON

Dr. Anthony Reiman, MD, SM, FRCPC
Saint John Regional Hospital
St. John, NB

Dr. Kerry Savage, MD
BC Cancer Agency
Vancouver, BC

Dr. Pamela Skrabek, MD, MSc, FRCPC
CancerCare Manitoba
Winnipeg, MB

OUR IMPACT



LYMPHOMA
CANADA

TURNING PATIENT VOICES INTO ACTION

2025 was a year defined by action, driven by the voices, experiences, and resilience of Canadians affected by lymphoma.

Lymphoma Canada continued to prioritize the delivery of essential education and support services to patients and families across the country. The ongoing guidance of our Scientific Advisory Board, Nursing Advisory Board, and Patient Family Advisory Committee has been instrumental in shaping our programs and ensuring they meet the evolving needs of the community. As we reflect on the past year, we are grateful for the continued partnership and support that has strengthened our impact and advanced our mission.

Your support helped ensure that no patient faced lymphoma alone. It empowered individuals to better understand their diagnoses, connect with peers who truly understand their journey, and participate in conversations that shape healthcare decisions. It also advanced research and advocacy efforts focused on improving outcomes today and for future generations.

We see the impact of this collective commitment in informed patients, supported families, stronger advocacy outcomes, and a growing national community united by purpose.

In the following pages, we share key indicators of our impact in 2025, followed by heartfelt messages from patients and caregivers whose lives have been touched by Lymphoma Canada's programs and services.

COMMUNITY AND REACH



Over 5,000
*educational event
participants*



Over 2M
*social media post
impressions*

PROGRAMS AND EDUCATION



~8,200 educational resources free of charge to patients and caregivers in both official languages



Over 100 hospitals and cancer centres across Canada that request our patient manuals to be distributed to their patients upon diagnosis with lymphoma



Hosted two national conferences (English and French) to expand access to education and support



Delivered nine expert-led educational webinars on key topics in lymphoma care



Facilitated three “Ask a Specialist” Q&A sessions to provide direct access to clinical expertise



Over \$45,000 invested in lymphoma research in 2025 with over \$2 million awarded in lymphoma grants and sponsorship over the years



Over 800 patients responding to surveys during the year



100% Participation in health technology assessments (HTAs) and policy submissions informed by patient input including:

Nivolumab	in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for the treatment of patients with previously untreated stage III or IV classical Hodgkin lymphoma.
Venetoclax	in combination with ibrutinib, indicated for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
Glofitamab	in combination with gemcitabine and oxaliplatin for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are not candidates for autologous stem cell transplant (ASCT).
Acalabrutinib	in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma.
Acalabrutinib	in combination with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukemia.
Brentuximab Vedotin	regimen (BrECADD) including etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone, for newly diagnosed Hodgkin Lymphoma patients.
Mosunetuzumab	for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.
Tafasitamab	in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma.

Additional feedback on provincial funding algorithms/proposed scope funding algorithms, including Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia, and feedback on 5 draft recommendations.



Join Our Mission

Progress happens when a community comes together. By supporting Lymphoma Canada, you help ensure that patients and families have access to trusted information, meaningful support, and hope for what lies ahead.

Get Involved



Become a Partner in Giving

Consider joining Lymphoma Canada's monthly giving program. Ongoing support plays a vital role in sustaining patient programs, advancing research, and strengthening advocacy efforts throughout the year.

Ways to Give



Stay Connected

Stay connected to a community that is informed and empowered. Through webinars, events, newsletters, and programs, you can continue to learn, share, and support those affected by lymphoma.

Connect



Make a Difference

Every contribution matters. Whether through a donation, volunteering your time, or sharing your story, your involvement helps improve the lives of Canadians affected by lymphoma.

Donate

To our donors, sponsors, healthcare professionals, volunteers, and community partners - thank you for your continued support and commitment.

THANK YOU!



LYMPHOMA
CANADA

HEARTFELT MESSAGES OF THANKS FROM PATIENTS

2025 was a year defined by the strength of our community. Every milestone we reached, every life we touched, and every voice we amplified was made possible by your unwavering support.

You gave more than time or resources, you gave hope. You gave comfort to newly diagnosed patients, clarity to overwhelmed caregivers, and courage to those navigating treatment. You fueled research that moved the science forward and stood beside us as we championed access to the care every patient deserves.



I have had Follicular Lymphoma for 21 years and I volunteered with Lymphoma Canada because I wanted to learn more about my lymphoma. I continue because I have gained so much more, including an appreciation of how fortunate I have been compared to what many other patients have experienced, the wonderful feeling when you help others, the many exceptional people both patients and LC staff and the opportunity to give back.

- Mary Jon Lachance, Follicular Lymphoma patient



Thank you for hosting this conference. I especially valued connecting with all the specialists. I live in a small town in BC, we have to travel further to see specialists. I'm not sure if anyone else in northern health received Car-T therapy so it was good to hear the questions from other patients & caregivers. Made me feel like my husband & I are not alone.

- Mary, Diffuse Large B-Cell Lymphoma patient



As my blood cancer was so rare and at stage 4, I couldn't find anyone with a similar type of cancer, making it increasingly difficult. I joined Lymphoma Canada's community to find support and connections.

- Harjeet, Subcutaneous Panniculitis-Like T-Cell Lymphoma patient



I encourage anyone facing a lymphoma diagnosis to have faith in their specialists — they truly have your back. Staying informed and connected has been so important to me, which is why I regularly participate in Lymphoma Canada's educational webinars and value being part of this community.

- Susan, Mantle Cell Lymphoma patient

PATIENT & CAREGIVER EDUCATION



LYMPHOMA
CANADA



In 2025, Lymphoma Canada distributed approximately **8,200 educational resources free of charge**, sharing them with patients, hospitals and cancer centres across Canada. These vital materials — including our Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma (HL), and Chronic Lymphocytic Leukemia (CLL) patient manuals are often the first source of education for newly diagnosed individuals, helping them better understand their diagnosis and treatment options. We also provide these resources directly to patients through one-on-one requests via our website and info@lymphoma.ca email, ensuring accessible, personalized support nationwide.



~8,200 educational resources distributed



22 new cancer centres in Canada added to our distribution list

Whether you're navigating a recent diagnosis, undergoing cancer treatment, or celebrating your triumph over lymphoma, Lymphoma Canada is here to provide an array of resources for you and your loved ones. Each year, we offer specialized support, aimed at empowering lymphoma patients and their caregivers to navigate the complexities of their health journey. Our accessible materials are available in English and French, offering a wealth of patient-centred resources and educational content on our website.

lymphoma.ca

WEBINAR SERIES







Throughout 2025, Lymphoma Canada delivered a comprehensive series of expert led webinars designed to support individuals across the full spectrum of the lymphoma and CLL journey, from diagnosis and treatment decision making to survivorship and quality of life.

As part of our ongoing commitment to delivering trusted, accessible education, the following educational sessions were hosted and reached and engaged over **1,300 registrants**:

- + Update from the 2024 American Society of Hematology (ASH) Conference
- + Understanding Therapy Coverage: A Pathway to Better Care
- + Nutrition and Wellness
- + Watch and Wait for Lymphoma and CLL Patients
- + Diffuse Large B-Cell Lymphoma: Treatment Options in Canada
- + Psychosocial Support for Patients
- + Relaxation and Stress Management
- + How Social Work Can Support your Lymphoma/CLL Journey
- + Nutrition and Wellness for Lymphoma/CLL Patients (French).



These sessions brought together leading clinicians and subject matter experts to provide timely, relevant, and practical education to patients and caregivers across Canada, helping them better understand their disease, navigate the healthcare system, and manage the physical and emotional impacts of lymphoma.

We extend our sincere gratitude to       for their generous sponsorship of our educational webinars.

9TH ANNUAL NATIONAL CONFERENCE FOR LYMPHOMA AND CLL PATIENTS

From October 15 to 17, 2025, Lymphoma Canada hosted its 9th Annual National Patient Conference on Lymphoma and CLL, bringing together patients, caregivers, and healthcare professionals from across the country for our largest educational event to date. Held virtually, the conference welcomed nearly 750 registrants, marking our most well attended conference to date.

Over three evenings, experts from across Canada delivered live, patient-focused sessions designed to inform, empower, and support individuals at every stage of their lymphoma and CLL journey. The schedule combined clinical insight with practical guidance, covering emerging treatments, clinical trials, targeted therapies, and evidence-based wellness strategies to help participants make informed decisions about their care.


Day one focused on building foundational understanding, with sessions tailored to newly diagnosed patients, immune health during treatment, and an overview of targeted therapies for lymphoma and CLL. The day also featured a dedicated patient and caregiver story, reinforcing the lived experience at the heart of the conference.

Day two explored lymphoma subtypes in greater depth, offering disease specific sessions on Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Waldenström Macroglobulinemia, and Cutaneous T Cell Lymphoma. Attendees had the opportunity to engage directly with experts through live Q&A sessions and learned more about accessing clinical trials in Canada.

Day three shifted the focus to health and wellness, addressing shared decision making, caregiver wellbeing, nutrition, and exercise for lymphoma patients. These sessions underscored the importance of wellness and supporting both patients and caregivers beyond clinical care.

By delivering the conference virtually and free of charge, Lymphoma Canada ensured broad accessibility, enabling participants from across Canada to gain valuable insights, furthering the commitment to providing high-quality education and support for those affected by lymphoma and CLL.

[Learn More](#)



Thank you to our generous sponsors of the National conference:

Platinum Sponsor	Gold Sponsor
Silver Sponsor	Bronze Sponsor

Other Sponsoring Partners



2025 FRANCOPHONE CONFERENCE ON LYMPHOMA AND CLL FOR PATIENTS

Lymphoma Canada hosted its 4th bi-annual Francophone Conference on November 12, welcoming over 150 registrants from across Canada. The virtual event was chaired by Dr. Eva Laverdure and provided accessible, expert led education tailored to Francophone/Quebec lymphoma and CLL patients and caregivers.

This free educational conference featured presentations from leading academics and healthcare specialists. Topics included disease and treatment specific information, the importance of knowing one's lymphoma subtype, an overview of targeted therapies for lymphoma and CLL, and strategies for managing symptoms and side effects.

[Learn More](#)

Thank you to our generous sponsors:

Gold Sponsor



Silver Sponsor



Bronze Sponsor



SUPPORT FOR PATIENTS & FAMILIES



LYMPHOMA
CANADA

Our diverse support programs, tailored to lymphoma and CLL patients as well as their caregivers, aim to foster connections within the community and offer invaluable support throughout the individual's lymphoma journey.

LYMPHOMA LINKS PEER-MENTORSHIP PROGRAM

Frequently we hear patients and caregivers say that they would benefit from speaking with someone who has been through a similar experience. In 2025, Lymphoma Canada continued to address the needs of patients and caregivers by facilitating connections through the *Lymphoma Links Peer-to-Peer Mentorship Program*. Patients and caregivers can either seek support as mentees or offer their guidance as mentors, sharing their personal experiences with lymphoma to help others navigate their journey. By fostering mutual support and understanding, Lymphoma Links ensures that patients and caregivers never have to face their journey alone. To get started, click this link below.

[Get Started](#)

ONLINE SUPPORT PROGRAMS

Lymphoma Canada continued to provide one-on-one information and support to patients and caregivers through various accessible channels, including email and phone assistance. We also maintained our monthly virtual support group, held on the first Wednesday of each month in collaboration with Wellspring Cancer Support, a Canadian non-profit specializing in cancer support. These sessions offer a welcoming and secure space where individuals can receive the assistance and emotional support they need. By creating opportunities for connection and guidance, Lymphoma Canada ensures that no one has to face their lymphoma journey alone. For more information, please visit our website at the link below.

[Learn More](#)



ASK A LYMPHOMA/CLL SPECIALIST Q&A PROGRAM

In 2025, Lymphoma Canada continued its Ask a Lymphoma/CLL Specialist Q&A program, providing patients and caregivers with direct access to Canadian lymphoma and CLL experts in a trusted, accessible virtual format. This ongoing program enables participants to ask questions in real time and receive reliable, evidence-based information to support informed decision making throughout their care journey.

On March 26, 2025, patients engaged with *Dr. Carolyn Owen*, associate professor in the division of hematology and hematological malignancies at the University of Calgary. The July 8 session featured *Dr. Pamela Skrabek*, hematologist with CancerCare Manitoba and assistant professor of internal medicine at the Max Rady College of Medicine. The final session, held on October 30, welcomed *Dr. Anthea Peters*, hematologist at the Cross Cancer Institute in Edmonton and associate professor in the Department of Oncology at the University of Alberta.

We extend our sincere gratitude to our generous sponsors for their support of our Ask a Lymphoma/CLL Specialist Q&A Program.



[Learn More](#)

SOUTHWESTERN ONTARIO CHAPTER

Three community meetings were held throughout the year by the Southwestern Ontario Chapter, a program run by and for lymphoma patients, their families, and caregivers. Hosted at the Village of Winston Park in Kitchener, these sessions created a supportive environment for members of the local lymphoma community to connect, share experiences, and build meaningful relationships. Each meeting also included educational components to help participants stay informed about treatment options and emerging research, strengthening the Chapter's role as both a peer support network and a trusted source of information.



ADVOCATING FOR EQUITABLE ACCESS TO INNOVATIVE THERAPIES



LYMPHOMA
CANADA

Advocacy remains a core pillar of Lymphoma Canada’s mission. In 2025, we continued our work to advance equitable access to innovative lymphoma and CLL therapies for patients across Canada, regardless of the province in which they may reside. Lymphoma Canada firmly believes that access to effective, life changing treatments should not depend on a patient’s postal code.

CANADA’S DRUG AGENCY (CDA) & INSTITUT NATIONAL D’EXCELLENCE EN SANTÉ ET EN SERVICES SOCIAUX (INESSS) SUBMISSIONS

What is a Health Technology Assessment (HTA)?

CLINICAL TRIALS → HEALTH CANADA APPROVAL → HTA → PROVINCIAL ACCESS

HTA decisions influence:

- Access to treatment
- Eligibility
- Wait times

That’s why patient input is essential.

Lymphoma Canada participates in 100% of HTA patient submissions.

Our Advocacy = Better Access

HTA submissions help:

1. Speed up access
2. Communicate patient preferences
3. Advocate for equitable access

Thousands benefit. And we’ll continue—100% of the time.

In Canada, lymphoma therapies are approved at the federal level by **Health Canada**, followed by health technology assessments conducted by **Canada’s Drug Agency** for provinces outside Quebec and **Institut national d’excellence en santé et en services sociaux** for Quebec. These assessments evaluate new therapies based on clinical effectiveness, economic value, and patient experience.

Throughout 2025, Lymphoma Canada participated in all available patient submission opportunities related to lymphoma and CLL therapies under review by these agencies. A key component of this work involved designing, promoting, and collecting national patient experience surveys to ensure the lived experiences of patients and caregivers were meaningfully represented in decision making processes.

By amplifying patient voices and translating real world experiences into actionable insights, Lymphoma Canada plays an essential role in informing funding decisions and advocating for timely, equitable access to new therapies. This work strengthens the patient perspective within health system decision making and supports better outcomes for Canadians affected by lymphoma.

For more information about Lymphoma Canada’s advocacy efforts, please contact info@lymphoma.ca.

WATCH AND WAIT AWARENESS AND ADVOCACY SURVEY

At the end of 2025, Lymphoma Canada launched a national Watch and Wait Awareness and Advocacy Survey to better understand the lived experiences of patients and caregivers navigating this phase of care. The survey places a particular focus on the emotional and mental health impacts of watch and wait for individuals living with indolent lymphomas and CLL.

Through this campaign, Lymphoma Canada aims to raise awareness of the mental health impact of watch

and wait, amplify patient and caregiver voices, and advocate for improved psychosocial and mental health supports as part of standard lymphoma and CLL care across Canada.

Findings from the survey will be analyzed and shared in a comprehensive report to inform advocacy efforts and support evidence-based discussions with healthcare decision makers.



Lymphoma Canada offers a comprehensive “Watch and Wait Guide” that provides practical information, and guidance for patients and caregivers navigating this phase of care.

ADVOCACY AND PARTNERSHIP FOR IMPROVED ACCESS TO TREATMENT

Lymphoma Canada continues to update its White Paper, *Access to Innovative Therapies in Canada*, to reflect emerging developments such as the Ontario Funding Accelerated for Specific Treatments (FAST) program and other changes in the treatment access

landscape. This important report examines ongoing challenges, provincial variations, and opportunities to improve the timely availability of novel therapies for people living with lymphoma and CLL across Canada.



LYMPHOMA RESEARCH & DISEASE AWARENESS



LYMPHOMA
CANADA

For years, Lymphoma Canada has played a meaningful role in advancing lymphoma research in Canada. Through targeted research grants and sustained knowledge-sharing, we support studies that strengthen healthcare systems, inform clinical decision-making, and improve outcomes for individuals living with lymphoma and CLL. Our research investments reflect a long-standing commitment to translating scientific inquiry into real-world patient impact.

2025 RESEARCH GRANT

In 2025, Lymphoma Canada continued its commitment to funding high-impact, well-defined research with the potential to improve healthcare delivery and patient outcomes in malignant lymphoproliferative diseases. Following a comprehensive review process by the Lymphoma Canada Research Award Review Committee, the 2025 research grant was awarded to **Dr. Anca Prica** for the project *Frailty and quality of life in patients undergoing CAR T therapy for Large B-cell lymphoma: A prospective study*, conducted at Princess Margaret Cancer Centre.

We extend our sincere thanks to all researchers who submitted thoughtful and innovative proposals. The quality of submissions reflects the strength and dedication of Canada's lymphoma research community.



Dr. Anca Prica



ADVANCING LYMPHOMA RESEARCH IN CANADA

Lymphoma Canada's Research Grants Impact Campaign highlighted the tangible outcomes of its research investments by showcasing innovative Canadian studies advancing lymphoma and CLL care. This initiative demonstrated how funded research is improving treatment approaches, deepening understanding of disease, and supporting better outcomes for patients and caregivers. By bringing attention to these projects, the campaign reinforced the critical role of research in shaping a more effective and responsive healthcare system.

Recent funded research projects include:

- 2020** Enhancing CAR-T Cell Therapy for Lymphoma Patients, *led by Dr. Sam Saibil and Dr. Rob Laister at Princess Margaret Cancer Centre*
- 2021** Improving Mantle Cell Lymphoma Treatment by Targeting Genetic Mutations, *led by Dr. Krysta Coyle at Simon Fraser University*
- 2021** Using Health Data to Improve Treatment Planning for CLL Patients, *led by Dr. Versha Banerji at CancerCare Manitoba*
- 2022** Understanding Second Cancer Risks to Guide Safer CLL Treatment Decisions, *led by Dr. Abi Vijenthira*
- 2022** Advancing Personalized Treatments for Patients with Rare PTCL-TFH Lymphoma, *led by Dr. Kerry Savage and her team at BC Cancer*
- 2023** Enhancing Radiation Therapy Safety to Support Bone Marrow Transplants, *led by Dr. Ingrid Spadinger at BC Cancer*
- 2023** Improving Treatment Options for ALK-Negative Anaplastic Large Cell Lymphoma Patients, *led by Dr. Robert Kridel and Dr. Tomohiro Aoki at University Health Network*
- 2024** Discovering How Genetic Differences Affect CAR-T Therapy Outcomes, *led by Dr. Robert Vanner and Dr. Rob Laister at University Health Network*

[Learn More](#)



Lymphoma Patients Sharing Their Stories to Highlight the Importance of Research

In 2025, Lymphoma Canada continued to amplify the voices of patients by sharing the stories of Judy and Jen, whose experiences with lymphoma illustrate the critical role research plays in improving care and outcomes. Through their openness, they helped deepen understanding of the realities faced by patients, including the challenges associated with rare and complex lymphoma diagnoses.

Their personal journeys reinforced why ongoing research investment is essential to advancing treatment options, strengthening health systems, and improving quality of life for those affected by lymphoma.

[Share Your Story](#)



IN THE SPOTLIGHT



LYMPHOMA
CANADA

Claudio Grossi, Vice Chair

Claudio Grossi brings extensive financial, governance, and international leadership expertise to his role as Vice Chair of Lymphoma Canada's Board of Directors. A CPA, CA, and holder of the ICD.D designation from the Institute of Corporate Directors, Mr. Grossi has also completed an MBA specializing in Finance and International Business. Over a career spanning more than 35 years, he has held senior business and financial leadership roles across Canada, the United States, and Europe, contributing to complex, large-scale organizations across multiple sectors.

Mr. Grossi is currently employed by Hitachi Rail and serves as a Board member of the builder and operator of the Hazel McCallion Hurontario Light Rail Transit system. He is also the Chief Financial Officer of the builder and operator of the RSSOM Ontario Line Subway system. His prior leadership experience includes serving as CFO of Novara Capital Inc., a fintech start-up focused on blockchain-based investment solutions, and as Managing Director of Finance for the 407 ETR Highway, where he led significant systems and operational transformations. Earlier in his career, he held executive finance roles within a publicly traded international biotechnology company, including leadership of its Italian and Spanish operations, and began his professional journey at Deloitte in audit and financial services.

Mr. Grossi has been a dedicated member of Lymphoma Canada's Board of Directors since 2017, joining the organization following the loss of his father to non-Hodgkin lymphoma. He served as Board Chair from 2019 to 2025, providing steady leadership during a period of organizational growth, expanded programming, and strengthened advocacy efforts. His personal connection to the cause continues to inform his commitment to ensuring that Lymphoma Canada remains financially sound, strategically focused, and responsive to the needs of patients and caregivers.

As Vice Chair, Mr. Grossi plays a key role in supporting strong governance, long-term sustainability, and effective decision-making across the organization. His financial acumen, global perspective, and unwavering dedication have been instrumental in advancing Lymphoma Canada's mission. We are grateful for his continued leadership and proud to recognize his enduring contributions to improving the lives of Canadians affected by lymphoma and CLL.



WORLD LYMPHOMA AWARENESS DAY

SEPTEMBER 15, 2025

On September 15, Lymphoma Canada joined communities across Canada and around the world to recognize World Lymphoma Awareness Day, raising awareness and standing in solidarity with those affected by lymphoma. This year, under the campaign theme “It’s Time to Get Honest About How We’re Feeling”, the lymphoma community came together to highlight the importance of honesty within support groups.

As part of this national awareness initiative, Lymphoma Canada once again lit Canada purple. In collaboration with landmarks across the country, buildings were illuminated in purple on September 15, 2025, to show support for the lymphoma community and amplify awareness nationwide.

Below is the list of participating landmarks:

BRITISH COLUMBIA (BC)

Fitzsimmons Creek Bridge
Fountain – Lafarge Lake
Legislative Assembly of BC
Parliament Buildings Port
Moody City Hall Sails of Light
Science World at Telus World
of Science BC Place and the
Vancouver Convention Centre

ALBERTA (AB)

Art Gallery of Alberta Calgary
Tower Lethbridge City Hall
Okotoks Municipal Centre
Reconciliation Bridge Red Deer
City Hall Telus Spark Science
Centre

MANITOBA (MB)

Legislative Building
Winnipeg Sign

NEWFOUNDLAND AND LABRADOR (NL)

Signal Hill St. John’s City Hall

NOVA SCOTIA (NS)

Halifax City Hall

ONTARIO (ON)

Absolute World Brampton City
Hall Clock Tower Brant Street
Pier Civic Centre Clock Tower
CN Tower Exhibition Place
Guelph City Hall / Market Square
Hamilton Sign Ottawa Markets
Peace Bridge Riverwalk
Commons and Fred A. Lundy
Bridge Toronto 3D Sign

PRINCE EDWARD ISLAND (PEI)

Charlottetown City Hall

NEW BRUNSWICK (NB)

Moncton, Downing Street, Subway
Block, Downtown Place and Avenir
Centre Resurgo Place – Moncton

INTERNATIONAL

Petra-Jordan

To learn more about the World Lymphoma Awareness Day campaign, please visit the event page.

[Learn More](#)



CN Tower



Broughton City Hall



Lethbridge City Hall



Moncton City Hall




Calgary Science Centre



Legislative Assembly of BC



Petra Jordan



Reconciliation Bridge




Resurgo Place



Sails of Light



Halifax City Hall



The Peace Bridge


Mary Jon Lachance

VOLUNTEER FOR OVER 15 YEARS

This year, we are proud to spotlight Mary Jon Lachance, a long-time volunteer, advocate, and pillar of the Lymphoma Canada community. Mary Jon has been living with Follicular Lymphoma for over two decades and has dedicated approximately 15 years to supporting Lymphoma Canada through a wide range of volunteer roles.

Mary Jon is a co-founder and former Chair of the Southwestern Ontario Chapter, a role she held for 13 years. Her contributions also include supporting conferences, serving as a peer mentor, participating on the Patient and Family Advisory Committee and the Patient Support and Research Committee, as well as ongoing fundraising and donor support. Her deep involvement reflects both her commitment to the organization and her desire to help others navigating a lymphoma diagnosis.

Mary Jon began volunteering to better understand her own lymphoma journey and continues because of the meaningful connections she has built and the opportunity to give back. Through her compassion, leadership, and generosity, she has helped strengthen Lymphoma Canada's programs and community. We are sincerely grateful to Mary Jon for her many years of dedication and for the impact she continues to make for patients, caregivers, and families affected by lymphoma.



[Get Involved](#)

Judy's Story of Strength: FINDING HOPE THROUGH KNOWLEDGE AND SUPPORT



In early 2017, Judy began experiencing persistent abdominal pain, night sweats, and unexplained weight loss. Like many patients, she initially dismissed the symptoms, but as the warning signs continued, it became clear something was wrong. After multiple tests and delayed answers, Judy received a life-changing diagnosis: Diffuse Large B-Cell Lymphoma.

Judy's journey was especially complex. A heart and lung transplant recipient, she faced an intense course of treatment that included chemotherapy, injections, and surgery. The physical and emotional toll was overwhelming, yet Judy remained determined to keep moving forward. Throughout the most difficult moments, the support of her family, friends, and community helped carry her through.

Equally important was access to trusted information. Through Lymphoma Canada's educational webinars and resources, Judy was able to better understand her diagnosis and treatment options. This knowledge gave her clarity, confidence, and hope at a time when uncertainty felt constant.

Today, Judy continues to rebuild her strength and independence. Her journey is a powerful reminder of the importance of early diagnosis, access to reliable education, and continued investment in lymphoma research. With your support, Lymphoma Canada can continue helping patients like Judy navigate their diagnosis with knowledge, support, and hope for the future.

[Support patients like Judy](#)

Community Strength in Action

NAV NAVUN MAO

Lymphoma Canada was deeply moved by the generosity and resilience of Nav, a lymphoma patient, who turned his personal journey into a powerful act of community support.

Diagnosed with Hodgkin's lymphoma in late 2024, Nav faced months of chemotherapy with quiet strength, determination, and unwavering positivity. Known for his strong work ethic, humour, and compassion, Nav chose to mark the completion of his treatment by giving back. In partnership with Lymphoma Canada, he organized a community fundraising initiative to support others facing lymphoma.

Funds raised through Nav's campaign directly support Lymphoma Canada's mission by helping to deliver patient education and support programs.

Nav's story is a powerful reminder that impact often begins with one person's decision to help others. We are sincerely grateful to Nav, his family, friends, and community for their generosity, courage, and commitment to making a difference.

Together, supporters like Nav strengthen the lymphoma community and help ensure that no one faces lymphoma alone.

For more information on how you can make a difference or host your own fundraising event, click the button below.

[Learn More](#)





\$215,258 was raised via events in 2025, including Laps Around Lymphoma and Par for the Cure

EVENTS SPOTLIGHT

**Laps Around Lymphoma
SEPTEMBER 15-30, 2025 / NATIONWIDE**

In September 2025, Lymphoma Canada once again united communities from coast to coast for the 6th Annual Laps Around Lymphoma virtual fitness challenge, bringing together participants who walked, fundraised, and rallied in support of the more than 100,000 Canadians living with lymphoma.

Throughout the challenge, supporters took thousands of steps to raise awareness and generate critical funds for patient programs, advocacy efforts, and research. The energy and commitment demonstrated by participants across the country reflected the strength of the lymphoma community and its shared determination to make a difference.

We extend our sincere thanks to every participant, donor, and advocate whose involvement made this year's event such a success.

As we celebrate the momentum of 2025, we're excited to announce that registration is now open for the 7th Annual Laps Around Lymphoma, taking place virtually from September 15-30, 2026. Join us again and be part of this movement for change. Register today and help us take another step toward a life unlimited by lymphoma.

Register Today



We are deeply grateful to our sponsors for their continued partnership and generosity, which helped make this national initiative possible.

Education Sponsors



Prize Sponsor



Par for the Cure Golf Tournament

JUNE 24, 2025 / CARRYING PLACE GOLF & COUNTRY CLUB, ON

Lymphoma Canada's 14th Annual Par for the Cure Golf Tournament was a meaningful success, bringing our community together for a day of connection, purpose, and impact at Carrying Place Golf and Country Club.

Golfers, supporters, patients, and partners joined us to continue a growing tradition of supporting Canadians affected by lymphoma. The day reflected the strength of our community and a shared commitment to advancing education, support, advocacy, and research.

Thanks to the generosity of our participants, donors, and sponsors, funds raised through this year's tournament help ensure that individuals and families affected by lymphoma have access to trusted information, support programs, and improved care across Canada.

We extend our sincere gratitude to our sponsors whose support played a key role in making this event possible.

Silver Sponsor

Hewmac Investments
in Memory of Michael Mulcahy

Lunch Sponsor

Judy & Sam Sapera

Putting Contest Sponsor



Hole Sponsors



LOOKING AHEAD

As we look to the year ahead, Lymphoma Canada remains grounded in one guiding principle: listening to and learning from the experiences of Canadians affected by lymphoma. Patients, caregivers, and loved ones each bring important perspectives, and it is through hearing these voices that we are able to understand evolving needs and respond in meaningful, relevant ways. Our focus will be on deepening these connections and ensuring that individuals across the country feel heard, supported, and represented.

We are committed to strengthening how we gather and act on patient and caregiver insights. Whether through direct engagement, surveys, advisory opportunities, or community outreach, these perspectives will continue to shape our programs, resources, and priorities. As the lymphoma landscape evolves, so too will our efforts to ensure that our support remains practical, accessible, and reflective of real-world experiences.

In the year ahead, we will continue to adapt and enhance our services to better support not only patients, but also those who stand alongside them. Recognizing the critical role of caregivers, families, and support networks, we will place greater emphasis on addressing their needs and ensuring they have access to the information and resources required throughout the care journey.

Our commitment is simple but essential: to listen, to respond, and to act. With the continued engagement of our community, we will ensure that the voices of those impacted by lymphoma remain at the heart of everything we do, guiding our work and strengthening our collective impact across Canada.

To support Lymphoma Canada, please click below to visit our website.

lymphoma.ca





LYMPHOMA
CANADA

December 31, 2025, audited financial statements are available at [lymphoma.ca](https://www.lymphoma.ca)
La version française du rapport annuel est disponible.

6860 Century Avenue, Suite 202 | Mississauga, ON L5N 2W5

Telephone 905.858.5967 Toll Free 1.866.659.5556

General inquiries info@lymphoma.ca | renseignement@lymphome.ca

Website [lymphoma.ca](https://www.lymphoma.ca) | [lymphome.ca](https://www.lymphome.ca)

Charitable Registration Number | 87346 1040 RR0001

Numéro d'entreprise du Québec | 1168812395

